<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>AVODARTÂ - dutasterideÂ capsule, liquid filledÂ </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use AVODART safely and effectively. See full prescribing information for AVODART.<br>Â <br>AVODART (dutasteride) Soft Gelatin Capsules<br>Initial U.S. Approval: 2001</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Indications and Usage, Limitations of Use (1.3) June 2011 </p>
<p class="Highlighta">Warnings and Precautions, Increased Risk of High-grade <br>Prostate Cancer (5.2) June 2011  </p>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">AVODART is a 5 alpha-reductase inhibitor indicated for the treatment of symptomatic <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">benign prostatic hyperplasia</span> (BPH) in men with an <span class="product-label-link" type="condition" conceptid="4093346" conceptname="Large prostate">enlarged prostate</span> to: (1.1)  (<a href="#section-1">1</a>)</p>
<ul>
<li>improve symptoms,</li>
<li>reduce the risk of acute <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, and</li>
<li>reduce the risk of the need for BPH-related surgery.</li>
</ul>
<p class="Highlighta">AVODART in combination with the alpha adrenergic antagonist, tamsulosin, is indicated for the treatment of symptomatic BPH in men with an <span class="product-label-link" type="condition" conceptid="4093346" conceptname="Large prostate">enlarged prostate</span>. (1.2)  (<a href="#section-1">1</a>)</p>
<p class="Highlighta">Limitations of Use: AVODART is not approved for the prevention of prostate cancer. (1.3)  (<a href="#section-1">1</a>)</p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">Monotherapy: 0.5Â mg once daily. (2.1)  (<a href="#section-2">2</a>)</p>
<p class="Highlighta">Combination with tamsulosin: 0.5Â mg once daily and tamsulosin 0.4Â mg once daily. (2.2)  (<a href="#section-2">2</a>)</p>
<p class="Highlighta">Dosing considerations: Swallow whole. May take with or without food. (2)  (<a href="#section-2">2</a>)</p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">0.5-mg soft gelatin capsules (3)  (<a href="#section-3">3</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li>Pregnancy and women of childbearing potential. (4, 5.4, 8.1)</li>
<li>Pediatric patients. (4)</li>
<li>Patients with previously demonstrated, clinically significant <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>) to AVODART or other 5 alpha-reductase inhibitors. (4)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>AVODART reduces serum prostate-specific antigen (PSA) concentration by approximately 50%. However, any confirmed increase in PSA while on AVODART may signal the presence of prostate cancer and should be evaluated, even if those values are still within the normal range for untreated men. (5.1)</li>
<li>AVODART may increase the risk of high-grade prostate cancer. (5.2, 6.1) </li>
<li>Assess patients to rule out other urological diseases, including prostate cancer, prior to prescribing AVODART. (5.3)</li>
<li>Women who are pregnant or could become pregnant should not handle AVODART Capsules due to potential risk to a male fetus. (5.4, 8.1)</li>
<li>Patients should not donate blood until 6Â months after their last dose of AVODART. (5.5)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions, reported in â‰¥1% of patients treated with AVODART and more commonly than in patients treated with placebo, are <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, decreased libido, <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">ejaculation disorders</span>, and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">breast disorders</span>. (6.1)  (<a href="#section-6">6</a>)</p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span>  (<a href="#section-6">6</a>)</p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Use with caution in patients taking potent, chronic CYP3A4 enzyme inhibitors (e.g., ritonavir). (7)  (<a href="#section-7">7</a>)</p></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 6/2011</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Monotherapy</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Combination With Alpha Adrenergic Antagonist</a></h2>
<h2><a href="#section-1.3" class="toc"><span class="XmChange">1.3 Limitations of Use</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Monotherapy</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Combination With Alpha Adrenergic Antagonist</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc"><span class="XmChange">5.1 Effects on Prostate-Specific Antigen (PSA) and the Use of PSA in Prostate Cancer Detection </span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="XmChange">5.2 Increased Risk of High-grade Prostate Cancer </span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Evaluation for Other Urological Diseases</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Exposure of Womenâ€”Risk to Male Fetus</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Blood Donation</a></h2>
<h2><a href="#section-5.6" class="toc">5.6Â  Effect on Semen Characteristics</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Cytochrome P450 3A Inhibitors</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Alpha Adrenergic Antagonists</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Calcium Channel Antagonists</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Cholestyramine</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Digoxin</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Warfarin</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Monotherapy</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Combination With Alpha-Blocker Therapy (CombAT)</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 PSA Monitoring</a></h2>
<h2><a href="#section-15.2" class="toc">17.2 Increased Risk of High-grade Prostate Cancer</a></h2>
<h2><a href="#section-15.3" class="toc">17.3 Exposure of Womenâ€”Risk to Male Fetus</a></h2>
<h2><a href="#section-15.4" class="toc">17.4 Blood Donation</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_a8c5c27f-dfd5-4154-98a2-49efbb953430"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fbd9c176-eff0-47e7-9ea7-acfd9cd3b369"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Monotherapy</h2>
<p class="First"> AVODART<span class="Sup">Â®</span> (dutasteride) Soft Gelatin Capsules are indicated for the treatment of symptomatic <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">benign prostatic hyperplasia</span> (BPH) in men with an <span class="product-label-link" type="condition" conceptid="4093346" conceptname="Large prostate">enlarged prostate</span> to:</p>
<ul>
<li>improve symptoms,</li>
<li>reduce the risk of acute <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> (AUR), and</li>
<li>reduce the risk of the need for BPH-related surgery.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_eb0b5126-9669-4761-a017-febec2baa200"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Combination With Alpha Adrenergic Antagonist</h2>
<p class="First"> AVODART in combination with the alpha adrenergic antagonist, tamsulosin, is indicated for the treatment of symptomatic BPH in men with an <span class="product-label-link" type="condition" conceptid="4093346" conceptname="Large prostate">enlarged prostate</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4131515b-6f31-4a0e-967c-397434a8bf9e"></a><a name="section-1.3"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">1.3 Limitations of Use</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"> AVODART is not approved for the prevention of prostate cancer.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_8515fa56-67b0-4273-9368-74288417b3f7"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First"> The capsules should be swallowed whole and not chewed or opened, as contact with the capsule contents may result in irritation of the oropharyngeal mucosa. AVODART may be administered with or without food.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f374e48f-fefc-4822-b61f-5f3e738a392d"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Monotherapy</h2>
<p class="First"> The recommended dose of AVODART is 1Â capsule (0.5Â mg) taken once daily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f7856741-c31a-4a1b-8f35-201a1819d4b4"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Combination With Alpha Adrenergic Antagonist</h2>
<p class="First"> The recommended dose of AVODART is 1Â capsule (0.5Â mg) taken once daily and tamsulosin 0.4Â mg taken once daily.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_6d3af228-ec0a-4e3b-b3fc-5e91dea8b63a"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First"> 0.5-mg, opaque, dull yellow, gelatin capsules imprinted with â€œGXÂ CE2â€? in red ink on one side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_f94e10b0-b985-4b99-9035-7530edfba125"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">AVODART is contraindicated for use in:</p>
<ul>
<li>Pregnancy. In animal reproduction and developmental toxicity studies, dutasteride inhibited development of male fetus external genitalia. Therefore, AVODART may cause fetal harm when administered to a pregnant woman. If AVODART is used during pregnancy or if the patient becomes pregnant while taking AVODART, the patient should be apprised of the potential hazard to the fetus <span class="Italics">[see Warnings and Precautions (5.4), Use in Specific Populations (8.1)]</span>.</li>
<li>Women of childbearing potential <span class="Italics">[see Warnings and Precautions (5.4), Use in Specific Populations (8.1)]</span>.</li>
<li>Pediatric patients <span class="Italics">[see Use in Specific Populations (8.4)]</span>.</li>
<li>Patients with previously demonstrated, clinically significant <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>) to AVODART or other 5 alpha-reductase inhibitors <span class="Italics">[see Adverse Reactions (6.2)]</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_7a22854a-affe-4732-9951-44c685e96556"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_757b62c4-9e00-4142-acb6-2116777fe1c7"></a><a name="section-5.1"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">5.1 Effects on Prostate-Specific Antigen (PSA) and the Use of PSA in Prostate Cancer Detection </span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">In clinical studies, AVODART reduced serum PSA concentration by approximately 50% within 3 to 6Â months of treatment. This decrease was predictable over the entire range of PSA values in patients with symptomatic BPH, although it may vary in individuals. AVODART may also cause decreases in serum PSA in the presence of prostate cancer. To interpret serial PSAs in men taking AVODART, a new PSA baseline should be established at least 3Â months after starting treatment and PSA monitored periodically thereafter. Any confirmed increase from the lowest PSA value while on AVODART may signal the presence of prostate cancer and should be evaluated, even if PSA levels are still within the normal range for men not taking a 5 alpha-reductase inhibitor. Noncompliance with AVODART may also affect PSA test results. </span></p>
<p style="border-left:1px solid;"><span class="XmChange">To interpret an isolated PSA value in a man treated with AVODART for 3Â months or more, the PSA value should be doubled for comparison with normal values in untreated men. </span></p>
<p style="border-left:1px solid;"><span class="XmChange">The free-to-total PSA ratio (percent free PSA) remains constant, even under the influence of AVODART. If clinicians elect to use percent free PSA as an aid in the detection of prostate cancer in men receiving AVODART, no adjustment to its value appears necessary. </span></p>
<p style="border-left:1px solid;"><span class="XmChange">Coadministration of dutasteride and tamsulosin resulted in similar changes to serum PSA as dutasteride monotherapy.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1a3052a9-4407-4b8a-a047-c2242464f194"></a><a name="section-5.2"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">5.2 Increased Risk of High-grade Prostate Cancer </span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">In men aged 50 to 75Â years with a prior negative biopsy for prostate cancer and a baseline PSA between 2.5Â ng/mL and 10.0Â ng/mL taking AVODART in the 4-year Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial, there was an increased incidence of Gleason score 8-10 prostate cancer compared with men taking placebo (AVODART 1.0% versus placebo 0.5%) <span class="Italics">[see Indications and Usage (1.3), Adverse Reactions (6.1)]</span>. In a 7-year placebo-controlled clinical trial with another 5 alpha-reductase inhibitor (finasteride 5Â mg, PROSCAR), similar results for Gleason score 8-10 prostate cancer were observed (finasteride 1.8% versus placebo 1.1%).</span></p>
<p style="border-left:1px solid;"><span class="XmChange"> 5 alpha-reductase inhibitors may increase the risk of development of high-grade prostate cancer. Whether the effect of 5 alpha-reductase inhibitors to reduce prostate volume, or study-related factors, impacted the results of these studies has not been established.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e4dd3983-455d-4c1f-b349-88c7013c6bda"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Evaluation for Other Urological Diseases</h2>
<p class="First"> Lower urinary tract symptoms of BPH can be indicative of other urological diseases, including prostate cancer. Patients should be assessed to rule out prostate cancer and other urological diseases prior to treatment with AVODART and periodically thereafter. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9127af1b-87be-44b7-9dc5-f80a54da4e30"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Exposure of Womenâ€”Risk to Male Fetus</h2>
<p class="First">Â  AVODART Capsules should not be handled by a woman who is pregnant or who could become pregnant. Dutasteride is absorbed through the skin and could result in unintended fetal exposure. If a woman who is pregnant or who could become pregnant comes in contact with leaking dutasteride capsules, the contact area should be washed immediately with soap and water <span class="Italics">[see Use in Specific Populations (8.1)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5559698c-df4d-4624-83fc-8a09bb454fe8"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Blood Donation</h2>
<p class="First"> Men being treated with AVODART should not donate blood until at least 6Â months have passed following their last dose. The purpose of this deferred period is to prevent administration of dutasteride to a pregnant female transfusion recipient.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9b20ca28-3f6b-4f4e-b807-204dc192f52c"></a><a name="section-5.6"></a><p></p>
<h2>5.6Â  Effect on Semen Characteristics</h2>
<p class="First"> The effects of dutasteride 0.5Â mg/day on semen characteristics were evaluated in normal volunteers aged 18 to 52 (nÂ =Â 27 dutasteride, nÂ =Â 23 placebo) throughout 52Â weeks of treatment and 24Â weeks of post-treatment follow-up. At 52Â weeks, the mean percent reductions from baseline in total sperm count, semen volume, and sperm motility were 23%, 26%, and 18%, respectively, in the dutasteride group when adjusted for changes from baseline in the placebo group. Sperm concentration and sperm morphology were unaffected. After 24Â weeks of follow-up, the mean percent change in total sperm count in the dutasteride group remained 23% lower than baseline. While mean values for all semen parameters at all time-points remained within the normal ranges and did not meet predefined criteria for a clinically significant change (30%), 2 subjects in the dutasteride group had decreases in sperm count of greater than 90% from baseline at 52Â weeks, with partial recovery at the 24-week follow-up. The clinical significance of dutasterideâ€™s effect on semen characteristics for an individual patientâ€™s fertility is not known.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_7cf2e290-2a15-400e-9607-cc4bf77f5579"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d3170759-4ff1-47c9-93fd-d5240daec398"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First"> Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trial of another drug and may not reflect the rates observed in practice.</p>
<p> From clinical trials with AVODART as monotherapy or in combination with tamsulosin:</p>
<ul>
<li>The most common adverse reactions reported in subjects receiving AVODART were <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, decreased libido, <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">breast disorders</span> (including <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span> and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>), and <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">ejaculation disorders</span>. The most common adverse reactions reported in subjects receiving combination therapy (AVODART plus tamsulosin) were <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, decreased libido, <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">breast disorders</span> (including <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span> and <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>), <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">ejaculation disorders</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">Ejaculation disorders</span> occurred significantly more in subjects receiving combination therapy (11%) compared with those receiving AVODART (2%) or tamsulosin (4%) as monotherapy.</li>
<li>Study withdrawal due to adverse reactions occurred in 4% of subjects receiving AVODART, and 3% of subjects receiving placebo in placebo-controlled trials with AVODART. The most common adverse reaction leading to study withdrawal was <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span> (1%).</li>
<li>In the clinical trial evaluating the combination therapy, study withdrawal due to adverse reactions occurred in 6% of subjects receiving combination therapy (AVODART plus tamsulosin) and 4% of subjects receiving AVODART or tamsulosin as monotherapy. The most common adverse reaction in all treatment arms leading to study withdrawal was <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span> (1% to 1.5%).</li>
</ul>
<p><span class="Underline">Monotherapy:</span> Over 4,300Â male subjects with BPH were randomly assigned to receive placebo or 0.5-mg daily doses of AVODART in three identical 2-year, placebo-controlled, double-blind, PhaseÂ 3 treatment studies, each followed by a 2-year open-label extension. During the double-blind treatment period, 2,167Â male subjects were exposed to AVODART, including 1,772 exposed for 1Â year and 1,510 exposed for 2Â years. When including the open-label extensions, 1,009Â male subjects were exposed to AVODART for 3Â years and 812 were exposed for 4Â years. The population was aged 47 to 94Â years (mean age: 66Â years) and greater than 90% were Caucasian. TableÂ 1 summarizes clinical adverse reactions reported in at least 1% of subjects receiving AVODART and at a higher incidence than subjects receiving placebo.</p>
<a name="id_8cf5d6be-5c64-4028-bb90-bad116810323"></a><table width="532.000">
<caption><span>Table 1. Adverse Reactions Reported in â‰¥1% of Subjects Over a 24-Month Period and More Frequently in the Group Receiving AVODART Than the Placebo Group (Randomized, Double-Blind, Placebo-Controlled Studies Pooled) by Time of Onset</span></caption>
<col width="29.9%">
<col width="17.5%">
<col width="16.5%">
<col width="17.5%">
<col width="18.6%">
<tfoot><tr class="Last"><td class="Botrule Lrule Rrule" align="left" colspan="5" rowspan="1" valign="top">
<span class="Sup">a</span> Includes <span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span> and <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="center" rowspan="2" valign="bottom">Adverse Reaction</td>
<td class="Botrule Rrule" align="center" colspan="4" rowspan="1" valign="bottom">Adverse Reaction Time of Onset</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" rowspan="1" valign="bottom">MonthsÂ 0-6</td>
<td class="Rrule" align="center" rowspan="1" valign="bottom">MonthsÂ 7-12</td>
<td class="Rrule" align="center" rowspan="1" valign="bottom">MonthsÂ 13-18</td>
<td class="Rrule" align="center" rowspan="1" valign="bottom">MonthsÂ 19-24</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" rowspan="1" valign="top">Â Â AVODART (n)</td>
<td class="Rrule" align="center" rowspan="1" valign="bottom">(nÂ =Â 2,167)</td>
<td class="Rrule" align="center" rowspan="1" valign="bottom">(nÂ =Â 1,901)</td>
<td class="Rrule" align="center" rowspan="1" valign="bottom">(nÂ =Â 1,725)</td>
<td class="Rrule" align="center" rowspan="1" valign="bottom">(nÂ =Â 1,605)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="1" valign="top">Â Â Placebo (n)</td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="bottom">(nÂ =Â 2,158)</td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="bottom">(nÂ =Â 1,922)</td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="bottom">(nÂ =Â 1,714)</td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="bottom">(nÂ =Â 1,555)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" rowspan="1" valign="top"><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span></td>
<td class="Rrule" align="center" rowspan="1" valign="bottom"></td>
<td class="Rrule" align="center" rowspan="1" valign="bottom"></td>
<td class="Rrule" align="center" rowspan="1" valign="bottom"></td>
<td class="Rrule" align="center" rowspan="1" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" rowspan="1" valign="top">Â Â AVODART</td>
<td class="Rrule" align="center" rowspan="1" valign="bottom">4.7%</td>
<td class="Rrule" align="center" rowspan="1" valign="bottom">1.4%</td>
<td class="Rrule" align="center" rowspan="1" valign="bottom">1.0%</td>
<td class="Rrule" align="center" rowspan="1" valign="bottom">0.8%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="1" valign="top">Â Â Placebo</td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="bottom">1.7%</td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="bottom">1.5%</td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="bottom">0.5%</td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="bottom">0.9%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" rowspan="1" valign="top">Decreased libido</td>
<td class="Rrule" align="center" rowspan="1" valign="bottom"></td>
<td class="Rrule" align="center" rowspan="1" valign="bottom"></td>
<td class="Rrule" align="center" rowspan="1" valign="bottom"></td>
<td class="Rrule" align="center" rowspan="1" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" rowspan="1" valign="top">Â Â AVODART</td>
<td class="Rrule" align="center" rowspan="1" valign="bottom">3.0%</td>
<td class="Rrule" align="center" rowspan="1" valign="bottom">0.7%</td>
<td class="Rrule" align="center" rowspan="1" valign="bottom">0.3%</td>
<td class="Rrule" align="center" rowspan="1" valign="bottom">0.3%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="1" valign="top">Â Â Placebo</td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="bottom">1.4%</td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="bottom">0.6%</td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="bottom">0.2%</td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="bottom">0.1%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" rowspan="1" valign="top"><span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">Ejaculation disorders</span></td>
<td class="Rrule" align="center" rowspan="1" valign="bottom"></td>
<td class="Rrule" align="center" rowspan="1" valign="bottom"></td>
<td class="Rrule" align="center" rowspan="1" valign="bottom"></td>
<td class="Rrule" align="center" rowspan="1" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" rowspan="1" valign="top">Â Â AVODART</td>
<td class="Rrule" align="center" rowspan="1" valign="bottom">1.4%</td>
<td class="Rrule" align="center" rowspan="1" valign="bottom">0.5%</td>
<td class="Rrule" align="center" rowspan="1" valign="bottom">0.5%</td>
<td class="Rrule" align="center" rowspan="1" valign="bottom">0.1%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="1" valign="top">Â Â Placebo</td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="bottom">0.5%</td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="bottom">0.3%</td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="bottom">0.1%</td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="bottom">0.0%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" rowspan="1" valign="top"><span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast disorders</span><span class="Sup">a</span>
</td>
<td class="Rrule" align="center" rowspan="1" valign="bottom"></td>
<td class="Rrule" align="center" rowspan="1" valign="bottom"></td>
<td class="Rrule" align="center" rowspan="1" valign="bottom"></td>
<td class="Rrule" align="center" rowspan="1" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" rowspan="1" valign="top">Â Â AVODART</td>
<td class="Rrule" align="center" rowspan="1" valign="bottom">0.5%</td>
<td class="Rrule" align="center" rowspan="1" valign="bottom">0.8%</td>
<td class="Rrule" align="center" rowspan="1" valign="bottom">1.1%</td>
<td class="Rrule" align="center" rowspan="1" valign="bottom">0.6%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" rowspan="1" valign="top">Â Â Placebo</td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="bottom">0.2%</td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="bottom">0.3%</td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="bottom">0.3%</td>
<td class="Botrule Rrule" align="center" rowspan="1" valign="bottom">0.1%</td>
</tr>
</tbody>
</table>
<p><span class="Italics">Long-Term Treatment (Up to 4 Years): </span><span class="Italics"> High-grade Prostate Cancer: </span>The REDUCE trial was a randomized, double-blind, placebo-controlled trial that enrolled 8,231 men aged 50 to 75Â years with a serum PSA of 2.5Â ng/mL to 10Â ng/mL and a negative prostate biopsy within the previous 6Â months. Subjects were randomized to receive placebo (NÂ =Â 4,126) or 0.5-mg daily doses of AVODART (NÂ =Â 4,105) for up to 4Â years. The mean age was 63Â years and 91% were Caucasian. Subjects underwent protocol-mandated scheduled prostate biopsies at 2 and 4Â years of treatment or had â€œfor-cause biopsiesâ€? at non-scheduled times if clinically indicated. There was a higher incidence of Gleason score 8-10 prostate cancer in men receiving AVODART (1.0%) compared with men on placebo (0.5%) <span class="Italics">[see Indications and Usage (1.3), Warnings and Precautions (5.2)]. </span>In a 7-year placebo-controlled clinical trial with another 5Â alpha-reductase inhibitor (finasteride 5Â mg, PROSCAR), similar results for Gleason score 8-10 prostate cancer were observed (finasteride 1.8% versus placebo 1.1%). </p>
<p>No clinical benefit has been demonstrated in patients with prostate cancer treated with AVODART. </p>
<p><span class="Underline"> Reproductive and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span>: </span>In the 3Â pivotal placebo-controlled BPH trials with AVODART, each 4Â years in duration, there was no evidence of increased sexual adverse reactions (<span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, decreased libido, and <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">ejaculation disorder</span>) or <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">breast disorders</span> with increased duration of treatment. Among these 3Â trials, there was 1Â case of breast cancer in the dutasteride group and 1Â case in the placebo group. No cases of breast cancer were reported in any treatment group in the 4-year CombAT trial or the 4-year REDUCE trial.</p>
<p> The relationship between long-term use of dutasteride and male breast neoplasia is currently unknown.</p>
<p><span class="Underline">Combination With Alpha-Blocker Therapy (CombAT):</span> Over 4,800Â male subjects with BPH were randomly assigned to receive 0.5-mg AVODART, 0.4-mg tamsulosin, or combination therapy (0.5-mg AVODART plus 0.4-mg tamsulosin) administered once daily in a 4-year double-blind study. Overall, 1,623Â subjects received monotherapy with AVODART; 1,611Â subjects received monotherapy with tamsulosin; and 1,610Â subjects received combination therapy. The population was aged 49 to 88Â years (mean age: 66Â years) and 88% were Caucasian. TableÂ 2 summarizes adverse reactions reported in at least 1% of subjects in the combination group and at a higher incidence than subjects receiving monotherapy with AVODART or tamsulosin.</p>
<a name="id_c6221878-5903-4e18-afce-21ff0849d5e0"></a><table border="single" width="477.000">
<caption><span>Table 2. Adverse Reactions Reported Over a 48-Month Period in â‰¥1% of Subjects and More Frequently in the Coadministration Therapy Group than the Groups Receiving Monotherapy With AVODART or Tamsulosin (CombAT) by Time of Onset</span></caption>
<col width="21.8%">
<col width="15.1%">
<col width="17.8%">
<col width="15.9%">
<col width="14.3%">
<col width="15.1%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="3" valign="bottom">Adverse Reaction</td>
<td class="Botrule Rrule" align="center" colspan="5" valign="top">Adverse Reaction Time of Onset</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" colspan="2" valign="top">YearÂ 1</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="bottom">YearÂ 2</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="bottom">YearÂ 3</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="bottom">YearÂ 4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">MonthsÂ 0-6</td>
<td class="Botrule Rrule" align="center" valign="top">MonthsÂ 7-12</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"> Combination<span class="Sup">a</span>
</td>
<td class="Rrule" align="center" valign="top">(nÂ =Â 1,610)</td>
<td class="Rrule" align="center" valign="top">(nÂ =Â 1,527)</td>
<td class="Rrule" align="center" valign="top">(nÂ =Â 1,428)</td>
<td class="Rrule" align="center" valign="top">(nÂ =Â 1,283)</td>
<td class="Rrule" align="center" valign="top">(nÂ =Â 1,200)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"> AVODART</td>
<td class="Rrule" align="center" valign="bottom">(nÂ =Â 1,623)</td>
<td class="Rrule" align="center" valign="bottom">(nÂ =Â 1,548)</td>
<td class="Rrule" align="center" valign="bottom">(nÂ =Â 1,464)</td>
<td class="Rrule" align="center" valign="bottom">(nÂ =Â 1,325)</td>
<td class="Rrule" align="center" valign="bottom">(nÂ =Â 1,200)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> Tamsulosin</td>
<td class="Botrule Rrule" align="center" valign="bottom">(nÂ =Â 1,611)</td>
<td class="Botrule Rrule" align="center" valign="bottom">(nÂ =Â 1,545)</td>
<td class="Botrule Rrule" align="center" valign="bottom">(nÂ =Â 1,468)</td>
<td class="Botrule Rrule" align="center" valign="bottom">(nÂ =Â 1,281)</td>
<td class="Botrule Rrule" align="center" valign="bottom">(nÂ =Â 1,112)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">Ejaculation disorders</span><span class="Sup">b</span>
</td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"> Combination</td>
<td class="Rrule" align="center" valign="bottom">7.8%</td>
<td class="Rrule" align="center" valign="bottom">1.6%</td>
<td class="Rrule" align="center" valign="bottom">1.0%</td>
<td class="Rrule" align="center" valign="bottom">0.5%</td>
<td class="Rrule" align="center" valign="bottom">&lt;0.1%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"> AVODART</td>
<td class="Rrule" align="center" valign="bottom">1.0%</td>
<td class="Rrule" align="center" valign="bottom">0.5%</td>
<td class="Rrule" align="center" valign="bottom">0.5%</td>
<td class="Rrule" align="center" valign="bottom">0.2%</td>
<td class="Rrule" align="center" valign="bottom">0.3%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> Tamsulosin</td>
<td class="Botrule Rrule" align="center" valign="bottom">2.2%</td>
<td class="Botrule Rrule" align="center" valign="bottom">0.5%</td>
<td class="Botrule Rrule" align="center" valign="bottom">0.5%</td>
<td class="Botrule Rrule" align="center" valign="bottom">0.2%</td>
<td class="Botrule Rrule" align="center" valign="bottom">0.3%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span><span class="Sup">c</span>
</td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"> Combination</td>
<td class="Rrule" align="center" valign="bottom">5.4%</td>
<td class="Rrule" align="center" valign="bottom">1.1%</td>
<td class="Rrule" align="center" valign="bottom">1.8%</td>
<td class="Rrule" align="center" valign="bottom">0.9%</td>
<td class="Rrule" align="center" valign="bottom">0.4%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"> AVODART</td>
<td class="Rrule" align="center" valign="bottom">4.0%</td>
<td class="Rrule" align="center" valign="bottom">1.1%</td>
<td class="Rrule" align="center" valign="bottom">1.6%</td>
<td class="Rrule" align="center" valign="bottom">0.6%</td>
<td class="Rrule" align="center" valign="bottom">0.3%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> Tamsulosin</td>
<td class="Botrule Rrule" align="center" valign="bottom">2.6%</td>
<td class="Botrule Rrule" align="center" valign="bottom">0.8%</td>
<td class="Botrule Rrule" align="center" valign="bottom">1.0%</td>
<td class="Botrule Rrule" align="center" valign="bottom">0.6%</td>
<td class="Botrule Rrule" align="center" valign="bottom">1.1%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Decreased libido<span class="Sup">d</span>
</td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"> Combination</td>
<td class="Rrule" align="center" valign="bottom">4.5%</td>
<td class="Rrule" align="center" valign="bottom">0.9%</td>
<td class="Rrule" align="center" valign="bottom">0.8%</td>
<td class="Rrule" align="center" valign="bottom">0.2%</td>
<td class="Rrule" align="center" valign="bottom">0.0%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"> AVODART</td>
<td class="Rrule" align="center" valign="bottom">3.1%</td>
<td class="Rrule" align="center" valign="bottom">0.7%</td>
<td class="Rrule" align="center" valign="bottom">1.0%</td>
<td class="Rrule" align="center" valign="bottom">0.2%</td>
<td class="Rrule" align="center" valign="bottom">0.0%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> Tamsulosin</td>
<td class="Botrule Rrule" align="center" valign="bottom">2.0%</td>
<td class="Botrule Rrule" align="center" valign="bottom">0.6%</td>
<td class="Botrule Rrule" align="center" valign="bottom">0.7%</td>
<td class="Botrule Rrule" align="center" valign="bottom">0.2%</td>
<td class="Botrule Rrule" align="center" valign="bottom">&lt;0.1%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast disorders</span><span class="Sup">e</span>
</td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"> Combination</td>
<td class="Rrule" align="center" valign="bottom">1.1%</td>
<td class="Rrule" align="center" valign="bottom">1.1%</td>
<td class="Rrule" align="center" valign="bottom">0.8%</td>
<td class="Rrule" align="center" valign="bottom">0.9%</td>
<td class="Rrule" align="center" valign="bottom">0.6%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"> AVODART</td>
<td class="Rrule" align="center" valign="bottom">0.9%</td>
<td class="Rrule" align="center" valign="bottom">0.9%</td>
<td class="Rrule" align="center" valign="bottom">1.2%</td>
<td class="Rrule" align="center" valign="bottom">0.5%</td>
<td class="Rrule" align="center" valign="bottom">0.7%</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"> Tamsulosin</td>
<td class="Botrule Rrule" align="center" valign="bottom">0.4%</td>
<td class="Botrule Rrule" align="center" valign="bottom">0.4%</td>
<td class="Botrule Rrule" align="center" valign="bottom">0.4%</td>
<td class="Botrule Rrule" align="center" valign="bottom">0.2%</td>
<td class="Botrule Rrule" align="center" valign="bottom">0.0%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
<td class="Rrule" align="center" valign="bottom"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"> Combination</td>
<td class="Rrule" align="center" valign="bottom">1.1%</td>
<td class="Rrule" align="center" valign="bottom">0.4%</td>
<td class="Rrule" align="center" valign="bottom">0.1%</td>
<td class="Rrule" align="center" valign="bottom">&lt;0.1%</td>
<td class="Rrule" align="center" valign="bottom">0.2%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"> AVODART</td>
<td class="Rrule" align="center" valign="bottom">0.5%</td>
<td class="Rrule" align="center" valign="bottom">0.3%</td>
<td class="Rrule" align="center" valign="bottom">0.1%</td>
<td class="Rrule" align="center" valign="bottom">&lt;0.1%</td>
<td class="Rrule" align="center" valign="bottom">&lt;0.1%</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"> Tamsulosin</td>
<td class="Rrule" align="center" valign="bottom">0.9%</td>
<td class="Rrule" align="center" valign="bottom">0.5%</td>
<td class="Rrule" align="center" valign="bottom">0.4%</td>
<td class="Rrule" align="center" valign="bottom">&lt;0.1%</td>
<td class="Botrule Rrule" align="center" valign="bottom">0.0%</td>
</tr>
</tbody>
</table>
<p><span class="Sup">a </span>Combination = AVODART 0.5Â mg once daily plus tamsulosin 0.4Â mg once daily.</p>
<p><span class="Sup">b </span>Includes <span class="product-label-link" type="condition" conceptid="4269918" conceptname="Orgasm incapacity">anorgasmia</span>, <span class="product-label-link" type="condition" conceptid="435866" conceptname="Retrograde ejaculation">retrograde ejaculation</span>, semen volume decreased, orgasmic sensation decreased, <span class="product-label-link" type="condition" conceptid="4090570" conceptname="Painful orgasm">orgasm abnormal</span>, <span class="product-label-link" type="condition" conceptid="4036117" conceptname="Late ejaculation">ejaculation delayed</span>, <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">ejaculation disorder</span>, <span class="product-label-link" type="condition" conceptid="4088757" conceptname="Anejaculation">ejaculation failure</span>, and <span class="product-label-link" type="condition" conceptid="434319" conceptname="Premature ejaculation">premature ejaculation</span>.</p>
<p><span class="Sup">c </span>Includes <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span> and disturbance in sexual arousal.</p>
<p><span class="Sup">d</span> Includes <span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">libido decreased</span>, <span class="product-label-link" type="condition" conceptid="4186941" conceptname="Sexual desire disorder">libido disorder</span>, <span class="product-label-link" type="condition" conceptid="4087317" conceptname="Lack of libido">loss of libido</span>, <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span>, and male <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span>.</p>
<p><span class="Sup">e </span>Includes <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, <span class="product-label-link" type="condition" conceptid="4114004" conceptname="Swelling of breast">breast swelling</span>, <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">breast pain</span>, <span class="product-label-link" type="condition" conceptid="4208409" conceptname="Breast tenderness">breast tenderness</span>, <span class="product-label-link" type="condition" conceptid="4021485" conceptname="Nipple tenderness">nipple pain</span>, and <span class="product-label-link" type="condition" conceptid="4156021" conceptname="Swelling of nipple">nipple swelling</span>.Â  </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span>:</span> In CombAT, after 4Â years of treatment, the incidence of the composite term <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> in the combination therapy group (12/1,610; 0.7%) was higher than in either monotherapy group: AVODART, 2/1,623 (0.1%) and tamsulosin, 9/1,611 (0.6%). Composite <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> was also examined in a separate 4-year placebo-controlled trial evaluating AVODART in men at risk for development of prostate cancer. The incidence of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> in subjects taking AVODART was 0.6% (26/4,105) compared with 0.4% (15/4,126) in subjects on placebo. A majority of subjects with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> in both studies had co-morbidities associated with an increased risk of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>. Therefore, the clinical significance of the numerical imbalances in <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> is unknown. No causal relationship between AVODART, alone or in combination with tamsulosin, and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> has been established. No imbalance was observed in the incidence of overall cardiovascular adverse events in either study.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6fe951a1-76cf-48b1-bfc1-d5ff7af9be0f"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of AVODART. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These reactions have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to AVODART.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4026047" conceptname="Sacral edema">localized edema</span>, serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>. </p>
<p><span class="Underline">Neoplasms: </span>Male breast cancer.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_6284bfdd-fea2-409a-a4e8-eb972e33ef7f"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fafb7a7a-70e6-4810-93fa-6900095fb9c7"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Cytochrome P450 3A Inhibitors</h2>
<p class="First">Dutasteride is extensively metabolized in humans by the CYP3A4 and CYP3A5 isoenzymes. The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. Because of the potential for drug-drug interactions, use caution when prescribing AVODART to patients taking potent, chronic CYP3A4 enzyme inhibitors (e.g., ritonavir) <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7038ec35-c330-4770-887f-c848d4fa50d0"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Alpha Adrenergic Antagonists</h2>
<p class="First">The administration of AVODART in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha adrenergic antagonist. The effect of administration of tamsulosin or terazosin on dutasteride pharmacokinetic parameters has not been evaluated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_57107d78-a198-4f15-acb9-209f5e642087"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Calcium Channel Antagonists</h2>
<p class="First">Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. The change in dutasteride exposure is not considered to be clinically significant. No dose adjustment is recommended<span class="Italics"> [see Clinical Pharmacology (12.3)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d22e5a57-92de-42a1-856d-9e32e382ed96"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Cholestyramine</h2>
<p class="First">Administration of a single 5-mg dose of AVODART followed 1Â hour later by 12Â g of cholestyramine does not affect the relative bioavailability of dutasteride <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2541f0d7-83f0-44e6-a191-1b927a86cb5d"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Digoxin</h2>
<p class="First">AVODART does not alter the steady-state pharmacokinetics of digoxin when administered concomitantly at a dose of 0.5Â mg/day for 3Â weeks <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_74ce5d97-02d8-4c99-90d1-a433c8bb1c89"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Warfarin</h2>
<p class="First">Concomitant administration of AVODART 0.5Â mg/day for 3Â weeks with warfarin does not alter the steady-state pharmacokinetics of the S- or R-warfarin isomers or alter the effect of warfarin on <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_23341bc9-c6d5-4fce-a1f3-decb50055282"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_a1f6bf41-1fcb-46b7-9542-59a45b00c136"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"> Pregnancy Category X. AVODART is contraindicated for use in women of childbearing potential and during pregnancy. AVODART is a 5 alpha-reductase inhibitor that prevents conversion of testosterone to dihydrotestosterone (DHT), a hormone necessary for normal development of male genitalia. In animal reproduction and developmental toxicity studies, dutasteride inhibited normal development of external genitalia in male fetuses. Therefore, AVODART may cause fetal harm when administered to a pregnant woman. If AVODART is used during pregnancy or if the patient becomes pregnant while taking AVODART, the patient should be apprised of the potential hazard to the fetus.</p>
<p> Abnormalities in the genitalia of male fetuses is an expected physiological consequence of inhibition of the conversion of testosterone to DHT by 5 alpha-reductase inhibitors. These results are similar to observations in male infants with genetic 5 alpha-reductase deficiency. Dutasteride is absorbed through the skin. To avoid potential fetal exposure, women who are pregnant or could become pregnant should not handle AVODART Soft Gelatin Capsules. If contact is made with leaking capsules, the contact area should be washed immediately with soap and water <span class="Italics">[see Warnings and Precautions (5.4)]</span>. Dutasteride is secreted into semen. The highest measured semen concentration of dutasteride in treated men was 14Â ng/mL. Assuming exposure of a 50-kg woman to 5Â mL of semen and 100% absorption, the womanâ€™s dutasteride concentration would be about 0.0175Â ng/mL. This concentration is more than 100Â times less than concentrations producing abnormalities of male genitalia in animal studies. Dutasteride is highly protein bound in human semen (greater than 96%), which may reduce the amount of dutasteride available for vaginal absorption.</p>
<p> In an embryo-fetal development study in female rats, oral administration of dutasteride at doses 10Â times less than the maximum recommended human dose (MRHD) of 0.5Â mg daily resulted in abnormalities of male genitalia in the fetus (decreased anogenital distance at 0.05Â mg/kg/day), nipple development, <span class="product-label-link" type="condition" conceptid="196528" conceptname="Hypospadias">hypospadias</span>, and distended preputial glands in male offspring (at all doses of 0.05, 2.5, 12.5, and 30Â mg/kg/day). An increase in stillborn pups was observed at 111Â times the MRHD, and reduced fetal body weight was observed at doses of about 15Â times the MRHD (animal dose of 2.5Â mg/kg/day). Increased incidences of skeletal variations considered to be delays in ossification associated with reduced body weight were observed at doses about 56Â times the MRHD (animal dose of 12.5Â mg/kg/day). </p>
<p> In a rabbit embryo-fetal study, doses 28- to 93-fold the MRHD (animal doses of 30, 100, and 200Â mg/kg/day) were administered orally during the period of major organogenesis (gestation days 7 to 29) to encompass the late period of external genitalia development. Histological evaluation of the genital papilla of fetuses revealed evidence of <span class="product-label-link" type="condition" conceptid="4140373" conceptname="Feminized male">feminization</span> of the male fetus at all doses. A second embryo-fetal study in rabbits at 0.3- to 53-fold the expected clinical exposure (animal doses of 0.05, 0.4, 3.0, and 30Â mg/kg/day) also produced evidence of <span class="product-label-link" type="condition" conceptid="4140373" conceptname="Feminized male">feminization</span> of the genitalia in male fetuses at all doses.</p>
<p> In an oral pre- and post-natal development study in rats, dutasteride doses of 0.05, 2.5, 12.5, or 30Â mg/kg/day were administered. Unequivocal evidence of <span class="product-label-link" type="condition" conceptid="4140373" conceptname="Feminized male">feminization</span> of the genitalia (i.e., decreased anogenital distance, increased incidence of <span class="product-label-link" type="condition" conceptid="196528" conceptname="Hypospadias">hypospadias</span>, nipple development) of male offspring occurred at 14- to 90-fold the MRHD (animal doses of 2.5Â mg/kg/day or greater). At 0.05-fold the expected clinical exposure (animal dose of 0.05Â mg/kg/day), evidence of <span class="product-label-link" type="condition" conceptid="4140373" conceptname="Feminized male">feminization</span> was limited to a small, but statistically significant, decrease in anogenital distance. Animal doses of 2.5 to 30Â mg/kg/day resulted in prolonged gestation in the parental females and a decrease in time to vaginal patency for female offspring and a decrease in prostate and seminal <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicle</span> weights in male offspring. Effects on newborn startle response were noted at doses greater than or equal to 12.5Â mg/kg/day. Increased <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirths</span> were noted at 30Â mg/kg/day.</p>
<p> In an embryo-fetal development study, pregnant rhesus monkeys were exposed intravenously to a dutasteride blood level comparable to the dutasteride concentration found in human semen. Dutasteride was administered on gestation days 20 to 100 at doses of 400, 780, 1,325, or 2,010Â ng/day (12Â monkeys/group). The development of male external genitalia of monkey offspring was not adversely affected. Reduction of fetal adrenal weights, reduction in fetal prostate weights, and increases in fetal ovarian and testis weights were observed at the highest dose tested in monkeys. Based on the highest measured semen concentration of dutasteride in treated men (14Â ng/mL), these doses represent 0.8 to 16Â times the potential maximum exposure of a 50-kg human female to 5Â mL semen daily from a dutasteride-treated man, assuming 100% absorption. (These calculations are based on blood levels of parent drug which are achieved at 32 to 186Â times the daily doses administered to pregnant monkeys on a ng/kg basis). Dutasteride is highly bound to proteins in human semen (greater than 96%), potentially reducing the amount of dutasteride available for vaginal absorption. It is not known whether rabbits or rhesus monkeys produce any of the major human metabolites.</p>
<p> Estimates of exposure multiples comparing animal studies to the MRHD for</p>
<p>dutasteride are based on clinical serum concentration at steady state.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_6c8b1326-4e56-4971-9258-390dbab1aeea"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First"> AVODART is contraindicated for use in women of childbearing potential, including nursing women. It is not known whether dutasteride is excreted in human milk.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_796de945-9ae8-43a5-8c6a-6d8700e85506"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">AVODART is contraindicated for use in pediatric patients. Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_28b7b46f-bf92-4f47-815f-dbb7c88082d2"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of 2,167Â male subjects treated with AVODART in 3Â clinical studies, 60% were aged 65 years and older and 15% were aged 75 years and older. No overall differences in safety or efficacy were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c62a97c1-fa2e-44d7-8de0-8f1b43b723b1"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No dose adjustment is necessary for AVODART in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_66353756-7c6b-4b71-a1a0-1df4f51bc938"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on dutasteride pharmacokinetics has not been studied. Because dutasteride is extensively metabolized, exposure could be higher in hepatically impaired patients. However, in a clinical study where 60Â subjects received 5Â mg (10Â times the therapeutic dose) daily for 24Â weeks, no additional adverse events were observed compared with those observed at the therapeutic dose of 0.5Â mg <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_f875cc37-e4be-42be-a2ff-39439687257a"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">In volunteer studies, single doses of dutasteride up to 40Â mg (80Â times the therapeutic dose) for 7Â days have been administered without significant safety concerns. In a clinical study, daily doses of 5Â mg (10Â times the therapeutic dose) were administered to 60Â subjects for 6Â months with no additional adverse effects to those seen at therapeutic doses of 0.5Â mg.</p>
<p>There is no specific antidote for dutasteride. Therefore, in cases of suspected overdosage symptomatic and supportive treatment should be given as appropriate, taking the long half-life of dutasteride into consideration.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_cdf3df4f-0f73-4f2a-895f-e4ee97954766"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First"> AVODART is a synthetic 4-azasteroid compound that is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5 alpha-reductase, an intracellular enzyme that converts testosterone to DHT.</p>
<p> Dutasteride is chemically designated as (5Î±,17Î²)-N-{2,5 bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide. The empirical formula of dutasteride is C<span class="Sub">27</span>H<span class="Sub">30</span>F<span class="Sub">6</span>N<span class="Sub">2</span>O<span class="Sub">2</span>, representing a molecular weight of 528.5 with the following structural formula:</p>
<div class="Figure"><img alt="Dutasteride structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=813507ec-1fc1-420f-ac5c-5c794b1059cd&amp;name=12b15be8-c3de-4732-b9a7-1c06c5e6c385-01.jpg"></div>
<p>Dutasteride is a white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow powder with a melting point of 242Â° to 250Â°C. It is soluble in ethanol (44Â mg/mL), methanol (64Â mg/mL), and polyethylene glycol 400 (3Â mg/mL), but it is insoluble in water.</p>
<p>Each AVODART Soft Gelatin Capsule, administered orally, contains 0.5Â mg of dutasteride dissolved in a mixture of mono-di-glycerides of caprylic/capric acid and butylated hydroxytoluene. The inactive excipients in the capsule shell are ferric oxide (yellow), gelatin (from certified BSE-free bovine sources), glycerin, and titanium dioxide. The soft gelatin capsules are printed with edible red ink.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_b0cd7f9a-f7d4-4a75-95f9-306304d32d8d"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_74227989-0aed-447b-9302-5ad16ed6886a"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First"> Dutasteride inhibits the conversion of testosterone to dihydrotestosterone (DHT). DHT is the androgen primarily responsible for the initial development and subsequent enlargement of the prostate gland. Testosterone is converted to DHT by the enzyme 5 alpha-reductase, which exists as 2Â isoforms, typeÂ 1 and typeÂ 2. The typeÂ 2 isoenzyme is primarily active in the reproductive tissues, while the typeÂ 1 isoenzyme is also responsible for testosterone conversion in the skin and liver. </p>
<p>Dutasteride is a competitive and specific inhibitor of both typeÂ 1 and typeÂ 2 5 alpha-reductase isoenzymes, with which it forms a stable enzyme complex. Dissociation from this complex has been evaluated under in vitro and in vivo conditions and is extremely slow. Dutasteride does not bind to the human androgen receptor.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_71bac43a-6c63-481f-97ae-a28893ab3b82"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First"><span class="Underline">Effect on 5 Alpha-Dihydrotestosterone and Testosterone:</span> The maximum effect of daily doses of dutasteride on the reduction of DHT is dose dependent and is observed within 1 to 2Â weeks. After 1 and 2Â weeks of daily dosing with dutasteride 0.5Â mg, median serum DHT concentrations were reduced by 85% and 90%, respectively. In patients with BPH treated with dutasteride 0.5Â mg/day for 4Â years, the median decrease in serum DHT was 94% at 1Â year, 93% at 2Â years, and 95% at both 3 and 4Â years. The median increase in serum testosterone was 19% at both 1 and 2Â years, 26% at 3Â years, and 22% at 4Â years, but the mean and median levels remained within the physiologic range.</p>
<p>In patients with BPH treated with 5Â mg/day of dutasteride or placebo for up to 12Â weeks prior to transurethral resection of the prostate, mean DHT concentrations in prostatic tissue were significantly lower in the dutasteride group compared with placebo (784 and 5,793Â pg/g, respectively, <span class="Italics">P</span>&lt;0.001). Mean prostatic tissue concentrations of testosterone were significantly higher in the dutasteride group compared with placebo (2,073 and 93Â pg/g, respectively, <span class="Italics">P</span>&lt;0.001).</p>
<p> Adult males with genetically inherited typeÂ 2 5 alpha-reductase deficiency also have decreased DHT levels. These 5 alpha-reductase deficient males have a small prostate gland throughout life and do not develop BPH. Except for the associated urogenital defects present at birth, no other clinical abnormalities related to 5 alpha-reductase deficiency have been observed in these individuals.</p>
<p><span class="Underline">Effects on Other Hormones:</span> In healthy volunteers, 52Â weeks of treatment with dutasteride 0.5Â mg/day (nÂ =Â 26) resulted in no clinically significant change compared with placebo (nÂ =Â 23) in sex hormone-binding globulin, estradiol, luteinizing hormone, follicle-stimulating hormone, thyroxine (free T4), and dehydroepiandrosterone. Statistically significant, baseline-adjusted mean increases compared with placebo were observed for total testosterone at 8Â weeks (97.1Â ng/dL, <span class="Italics">P</span>&lt;0.003) and thyroid-stimulating hormone at 52Â weeks (0.4Â mcIU/mL, <span class="Italics">P</span>&lt;0.05). The median percentage changes from baseline within the dutasteride group were 17.9% for testosterone at 8Â weeks and 12.4% for thyroid-stimulating hormone at 52Â weeks. After stopping dutasteride for 24Â weeks, the mean levels of testosterone and thyroid-stimulating hormone had returned to baseline in the group of subjects with available data at the visit. In patients with BPH treated with dutasteride in a large randomized, double-blind, placebo-controlled study, there was a median percent increase in luteinizing hormone of 12% at 6Â months and 19% at both 12 and 24Â months.</p>
<p><span class="Underline">Other Effects:</span> Plasma lipid panel and bone mineral density were evaluated following 52Â weeks of dutasteride 0.5Â mg once daily in healthy volunteers. There was no change in bone mineral density as measured by dual energy x-ray absorptiometry compared with either placebo or baseline. In addition, the plasma lipid profile (i.e., total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, low density lipoproteins, high density lipoproteins, and triglycerides) was unaffected by dutasteride. No clinically significant changes in adrenal hormone responses to ACTH stimulation were observed in a subset population (nÂ =Â 13) of the 1-year healthy volunteer study.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_1c603c9c-5485-47ec-81bd-09a81da5bb09"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Underline">Absorption:</span> Following administration of a single 0.5-mg dose of a soft gelatin capsule, time to peak serum concentrations (T<span class="Sub">max</span>) of dutasteride occurs within 2 to 3Â hours. Absolute bioavailability in 5Â healthy subjects is approximately 60% (range: 40% to 94%). When the drug is administered with food, the maximum serum concentrations were reduced by 10% to 15%. This reduction is of no clinical significance.</p>
<p><span class="Underline">Distribution:</span> Pharmacokinetic data following single and repeat oral doses show that dutasteride has a large volume of distribution (300 to 500Â L). Dutasteride is highly bound to plasma albumin (99.0%) and alpha-1 acid glycoprotein (96.6%).</p>
<p>In a study of healthy subjects (nÂ =Â 26) receiving dutasteride 0.5Â mg/day for 12Â months, semen dutasteride concentrations averaged 3.4Â ng/mL (range: 0.4 to 14 ng/mL) at 12Â months and, similar to serum, achieved steady-state concentrations at 6Â months. On average, at 12Â months 11.5% of serum dutasteride concentrations partitioned into semen.</p>
<p><span class="Underline">Metabolism and Elimination:</span> Dutasteride is extensively metabolized in humans. In vitro studies showed that dutasteride is metabolized by the CYP3A4 and CYP3A5 isoenzymes. Both of these isoenzymes produced the 4â€²-hydroxydutasteride, 6-hydroxydutasteride, and the 6,4â€²-dihydroxydutasteride metabolites. In addition, the 15-hydroxydutasteride metabolite was formed by CYP3A4. Dutasteride is not metabolized in vitro by human cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2E1. In human serum following dosing to steady state, unchanged dutasteride, 3Â major metabolites (4â€²-hydroxydutasteride, 1,2-dihydrodutasteride, and 6-hydroxydutasteride), and 2Â minor metabolites (6,4â€²-dihydroxydutasteride and 15-hydroxydutasteride), as assessed by <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> spectrometric response, have been detected. The absolute stereochemistry of the hydroxyl additions in the 6 and 15Â positions is not known. In vitro, the 4â€²-hydroxydutasteride and 1,2-dihydrodutasteride metabolites are much less potent than dutasteride against both isoforms of human 5 alpha-reductase. The activity of 6Î²-hydroxydutasteride is comparable to that of dutasteride.</p>
<p>Dutasteride and its metabolites were excreted mainly in feces. As a percent of dose, there was approximately 5% unchanged dutasteride (~1% to ~15%) and 40% as dutasteride-related metabolites (~2% to ~90%). Only trace amounts of unchanged dutasteride were found in urine (&lt;1%). Therefore, on average, the dose unaccounted for approximated 55% (range, 5% to 97%).</p>
<p>The terminal elimination half-life of dutasteride is approximately 5Â weeks at steady state. The average steady-state serum dutasteride concentration was 40Â ng/mL following 0.5Â mg/day for 1Â year. Following daily dosing, dutasteride serum concentrations achieve 65% of steady-state concentration after 1Â month and approximately 90% after 3Â months. Due to the long half-life of dutasteride, serum concentrations remain detectable (greater than 0.1Â ng/mL) for up to 4 to 6Â months after discontinuation of treatment.</p>
<p><span class="Underline">Specific Populations:</span><span class="Italics"> Pediatric: </span>Dutasteride pharmacokinetics have not been investigated in subjects younger than 18Â years.</p>
<p><span class="Italics">Geriatric: </span>No dose adjustment is necessary in the elderly. The pharmacokinetics and pharmacodynamics of dutasteride were evaluated in 36Â healthy male subjects aged between 24 and 87Â years following administration of a single 5-mgÂ dose of dutasteride. In this single-dose study, dutasteride half-life increased with age (approximately 170Â hours in men aged 20 to 49Â years, approximately 260Â hours in men aged 50 to 69Â years, and approximately 300Â hours in men older than 70Â years). Of 2,167Â men treated with dutasteride in the 3Â pivotal studies, 60% were age 65 and over and 15% were age 75 and over. No overall differences in safety or efficacy were observed between these patients and younger patients.</p>
<p><span class="Italics">Gender: </span>AVODART is contraindicated in pregnancy and women of childbearing potential and is not indicated for use in other women <span class="Italics">[see Contraindications (4), Warnings and Precautions (5.1)]</span>. The pharmacokinetics of dutasteride in women have not been studied.</p>
<p><span class="Italics">Race: </span>The effect of race on dutasteride pharmacokinetics has not been studied.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: </span>The effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> on dutasteride pharmacokinetics has not been studied. However, less than 0.1% of a steady-state 0.5-mg dose of dutasteride is recovered in human urine, so no adjustment in dosage is anticipated for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: </span>The effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on dutasteride pharmacokinetics has not been studied. Because dutasteride is extensively metabolized, exposure could be higher in hepatically impaired patients.</p>
<p><span class="Underline">Drug Interactions:</span> Â </p>
<p><span class="Italics"> Cytochrome P450 Inhibitors:</span>No clinical drug interaction studies have been performed to evaluate the impact of CYP3A enzyme inhibitors on dutasteride pharmacokinetics. However, based on in vitro data, blood concentrations of dutasteride may increase in the presence of inhibitors of CYP3A4/5 such as ritonavir, ketoconazole, verapamil, diltiazem, cimetidine, troleandomycin, and ciprofloxacin.</p>
<p>Dutasteride does not inhibit the in vitro metabolism of model substrates for the major human cytochrome P450 isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) at a concentration of 1,000Â ng/mL, 25Â times greater than steady-state serum concentrations in humans.</p>
<p><span class="Italics">Alpha Adrenergic Antagonists: </span>In a single-sequence, crossover study in healthy volunteers, the administration of tamsulosin or terazosin in combination with AVODART had no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. Although the effect of administration of tamsulosin or terazosin on dutasteride pharmacokinetic parameters was not evaluated, the percent change in DHT concentrations was similar for AVODART alone compared with the combination treatment.</p>
<p><span class="Italics">Calcium Channel Antagonists: </span>In a population pharmacokinetics analysis, a decrease in clearance of dutasteride was noted when coadministered with the CYP3A4 inhibitors verapamil (-37%, nÂ =Â 6) and diltiazem (-44%, nÂ =Â 5). In contrast, no decrease in clearance was seen when amlodipine, another calcium channel antagonist that is not a CYP3A4 inhibitor, was coadministered with dutasteride (+7%, nÂ =Â 4).</p>
<p>The decrease in clearance and subsequent increase in exposure to dutasteride in the presence of verapamil and diltiazem is not considered to be clinically significant. No dose adjustment is recommended.</p>
<p><span class="Italics">Cholestyramine: </span>Administration of a single 5-mg dose of AVODART followed 1Â hour later by 12Â g cholestyramine did not affect the relative bioavailability of dutasteride in 12Â normal volunteers.</p>
<p><span class="Italics">Digoxin: </span>In a study of 20Â healthy volunteers, AVODART did not alter the steady-state pharmacokinetics of digoxin when administered concomitantly at a dose of 0.5Â mg/day for 3Â weeks.</p>
<p><span class="Italics">Warfarin: </span>In a study of 23Â healthy volunteers, 3Â weeks of treatment with AVODART 0.5Â mg/day did not alter the steady-state pharmacokinetics of the S- or R-warfarin isomers or alter the effect of warfarin on <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time when administered with warfarin.</p>
<p><span class="Italics">Other Concomitant Therapy:</span> Although specific interaction studies were not performed with other compounds, approximately 90% of the subjects in the 3Â randomized, double-blind, placebo-controlled safety and efficacy studies receiving AVODART were taking other medications concomitantly. No clinically significant adverse interactions could be attributed to the combination of AVODART and concurrent therapy when AVODART was coadministered with anti-hyperlipidemics, angiotensin-converting enzyme (ACE) inhibitors, beta-adrenergic blocking agents, calcium channel blockers, corticosteroids, diuretics, nonsteroidal anti-inflammatory drugs (NSAIDs), phosphodiesterase Type V inhibitors, and quinolone antibiotics.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_d02369b5-22ad-4126-bed2-ba57b69dad45"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_0f920273-e572-4563-83dd-f79d7d097a1a"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Underline">Carcinogenesis:</span> A 2-year carcinogenicity study was conducted in B6C3F1 mice at doses of 3, 35, 250, and 500Â mg/kg/day for males and 3, 35, and 250Â mg/kg/day for females; an increased incidence of benign <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenomas</span> was noted at 250Â mg/kg/day (290-fold the MRHD of a 0.5-mg daily dose) in female mice only.Â  Two of the 3Â major human metabolites have been detected in mice. The exposure to these metabolites in mice is either lower than in humans or is not known.</p>
<p> In a 2-year carcinogenicity study in Han Wistar rats, at doses of 1.5, 7.5, and 53Â mg/kg/day in males and 0.8, 6.3, and 15Â mg/kg/day in females, there was an increase in Leydig cell <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> in the testes at 135-fold the MRHD (53Â mg/kg/day and greater). An increased incidence of Leydig cell <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> was present at 52-fold the MRHD (male rat doses of 7.5Â mg/kg/day and greater). A positive correlation between proliferative changes in the Leydig cells and an increase in circulating luteinizing hormone levels has been demonstrated with 5 alpha-reductase inhibitors and is consistent with an effect on the hypothalamic-pituitary-testicular axis following 5 alpha-reductase inhibition. At tumorigenic doses, luteinizing hormone levels in rats were increased by 167%. In this study, the major human metabolites were tested for carcinogenicity at approximately 1 to 3Â times the expected clinical exposure.</p>
<p><span class="Underline">Mutagenesis:</span> Dutasteride was tested for genotoxicity in a bacterial mutagenesis assay (Ames test), a chromosomal aberration assay in CHO cells, and a micronucleus assay in rats. The results did not indicate any genotoxic potential of the parent drug. Two major human metabolites were also negative in either the Ames test or an abbreviated Ames test.</p>
<p><span class="Underline">Impairment of Fertility:</span> Treatment of sexually mature male rats with dutasteride at 0.1- to 110-fold the MRHD (animal doses of 0.05, 10, 50, and 500Â mg/kg/day for up to 31Â weeks) resulted in dose- and time-dependent decreases in fertility; reduced cauda epididymal (absolute) sperm counts but not sperm concentration (at 50 and 500Â mg/kg/day); reduced weights of the epididymis, prostate, and seminal <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span>; and microscopic changes in the male reproductive organs. The fertility effects were reversed by recovery week 6 at all doses, and sperm counts were normal at the end of a 14-week recovery period. The 5 alpha-reductaseâ€“related changes consisted of cytoplasmic vacuolation of tubular epithelium in the epididymides and decreased cytoplasmic content of epithelium, consistent with decreased secretory activity in the prostate and seminal <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span>. The microscopic changes were no longer present at recovery week 14 in the low-dose group and were partly recovered in the remaining treatment groups. Low levels of dutasteride (0.6 to 17Â ng/mL) were detected in the serum of untreated female rats mated to males dosed at 10, 50, or 500Â mg/kg/day for 29 to 30Â weeks. In a fertility study in female rats, oral administration of dutasteride at doses of 0.05, 2.5, 12.5, and 30Â mg/kg/day resulted in reduced litter size, increased embryo resorption, and <span class="product-label-link" type="condition" conceptid="4140373" conceptname="Feminized male">feminization</span> of male fetuses (decreased anogenital distance) at 2- to 10-fold the MRHD (animal doses of 2.5Â mg/kg/day or greater). Fetal body weights were also reduced at less than 0.02-fold the MRHD in rats (0.5Â mg/kg/day).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_89448548-b3c3-4ade-b1ae-7e1ae7637ff3"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First"><span class="Underline">Central Nervous System Toxicology Studies:</span> In rats and dogs, repeated oral administration of dutasteride resulted in some animals showing signs of non-specific, reversible, centrally-mediated toxicity without associated histopathological changes at exposures 425- and 315-fold the expected clinical exposure (of parent drug), respectively.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_6b1abc6d-f37b-4dca-8d70-5399c05af8f2"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_387a00b3-e900-4688-8bb4-3e7c0c4e1338"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Monotherapy</h2>
<p class="First">AVODART 0.5 mg/day (nÂ =Â 2,167) or placebo (nÂ =Â 2,158) was evaluated in male subjects with BPH in three 2-year multicenter, placebo-controlled, double-blind studies, each with 2-year open-label extensions (nÂ =Â 2,340). More than 90% of the study population was Caucasian. Subjects were at least 50Â years of age with a serum PSA â‰¥1.5Â ng/mL and &lt;10Â ng/mL and BPH diagnosed by medical history and physical examination, including <span class="product-label-link" type="condition" conceptid="4093346" conceptname="Large prostate">enlarged prostate</span> (â‰¥30Â cc) and BPH symptoms that were moderate to severe according to the American Urological Association Symptom Index (AUA-SI). Most of the 4,325Â subjects randomly assigned to receive either dutasteride or placebo completed 2Â years of double-blind treatment (70% and 67%, respectively). Most of the 2,340Â subjects in the study extensions completed 2 additional years of open-label treatment (71%).</p>
<p><span class="Underline">Effect on Symptom Scores:</span> Symptoms were quantified using the AUA-SI, a questionnaire that evaluates urinary symptoms (incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>) by rating on a 0 to 5 scale for a total possible score of 35, with higher numerical total symptom scores representing greater severity of symptoms. The baseline AUA-SI score across the 3Â studies was approximately 17Â units in both treatment groups. Subjects receiving dutasteride achieved statistically significant improvement in symptoms versus placebo by MonthÂ 3 in 1 study and by MonthÂ 12 in the other 2Â pivotal studies. At MonthÂ 12, the mean decrease from baseline in AUA-SI total symptom scores across the 3Â studies pooled was -3.3Â units for dutasteride and -2.0Â units for placebo with a mean difference between the 2Â treatment groups of -1.3 (range: -1.1 to -1.5Â units in each of the 3Â studies, <span class="Italics">P</span>&lt;0.001) and was consistent across the 3Â studies. At MonthÂ 24, the mean decrease from baseline was -3.8Â units for dutasteride and -1.7Â units for placebo with a mean difference of -2.1 (range: -1.9 to -2.2 units in each of the 3Â studies, <span class="Italics">P</span>&lt;0.001). See FigureÂ 1. The improvement in BPH symptoms seen during the first 2Â years of double-blind treatment was maintained throughout an additional 2Â years of open-label extension studies.</p>
<p> These studies were prospectively designed to evaluate effects on symptoms based on prostate size at baseline. In men with prostate volumes â‰¥40Â cc, the mean decrease was -3.8Â units for dutasteride and -1.6Â units for placebo, with a mean difference between the 2Â treatment groups of -2.2 at MonthÂ 24. In men with prostate volumes &lt;40Â cc, the mean decrease was -3.7Â units for dutasteride and -2.2Â units for placebo, with a mean difference between the 2Â treatment groups of -1.5 at MonthÂ 24.</p>
<p><span class="Bold">Figure 1. AUA-SI Score<span class="Sup">a</span> Change From Baseline (Randomized, Double-Blind, Placebo-Controlled Studies Pooled)</span></p>
<div class="Figure"><img alt="Figure 1. AUA-SI Score* Change from Baseline (Randomized, Double-Blind, Placebo-Controlled Studies Pooled)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=813507ec-1fc1-420f-ac5c-5c794b1059cd&amp;name=12b15be8-c3de-4732-b9a7-1c06c5e6c385-02.jpg"></div>
<p><span class="Sup">a</span> AUA-SI score ranges from 0 to 35.</p>
<p><span class="Underline">Effect on Acute <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary Retention</span> and the Need for BPH-Related Surgery:</span> Efficacy was also assessed after 2Â years of treatment by the incidence of AUR requiring catheterization and BPH-related urological <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span>. Compared with placebo, AVODART was associated with a statistically significantly lower incidence of AUR (1.8% for AVODART vs. 4.2% for placebo, <span class="Italics">P</span>&lt;0.001; 57% reduction in risk, [95% CI: 38% to 71%]) and with a statistically significantly lower incidence of surgery (2.2% for AVODART vs. 4.1% for placebo, <span class="Italics">P</span>&lt;0.001; 48% reduction in risk, [95% CI: 26% to 63%]). See FiguresÂ 2 and 3.</p>
<p><span class="Bold">Figure 2. Percent of Subjects Developing Acute <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary Retention</span> Over a 24-Month Period (Randomized, Double-Blind, Placebo-Controlled Studies Pooled)</span></p>
<div class="Figure"><img alt="Figure 2. Percent of Subjects Developing Acute <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary Retention</span> Over a 24-Month Period (Randomized, Double-Blind, Placebo-Controlled Studies Pooled)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=813507ec-1fc1-420f-ac5c-5c794b1059cd&amp;name=12b15be8-c3de-4732-b9a7-1c06c5e6c385-03.jpg"></div>
<p><span class="Bold">Figure 3. Percent of Subjects Having Surgery for <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">Benign Prostatic Hyperplasia</span> Over a 24-Month Period (Randomized, Double-Blind, Placebo-Controlled Studies Pooled)</span></p>
<div class="Figure"><img alt="Figure 3. Percent of Subjects Having Surgery for <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">Benign Prostatic Hyperplasia</span> Over a 24-Month Period (Randomized, Double-Blind, Placebo-Controlled Studies Pooled)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=813507ec-1fc1-420f-ac5c-5c794b1059cd&amp;name=12b15be8-c3de-4732-b9a7-1c06c5e6c385-04.jpg"></div>
<p><span class="Underline">Effect on Prostate Volume:</span> A prostate volume of at least 30Â cc measured by transrectal ultrasound was required for study entry. The mean prostate volume at study entry was approximately 54Â cc.</p>
<p>Statistically significant differences (AVODART versus placebo) were noted at the earliest post-treatment prostate volume measurement in each study (MonthÂ 1, MonthÂ 3, or MonthÂ 6) and continued through MonthÂ 24. At MonthÂ 12, the mean percent change in prostate volume across the 3Â studies pooled was -24.7% for dutasteride and -3.4% for placebo; the mean difference (dutasteride minus placebo) was -21.3% (range: -21.0% to -21.6% in each of the 3Â studies, <span class="Italics">P</span>&lt;0.001). At MonthÂ 24, the mean percent change in prostate volume across the 3Â studies pooled was -26.7% for dutasteride and -2.2% for placebo with a mean difference of -24.5% (range: -24.0% to -25.1% in each of the 3Â studies, <span class="Italics">P</span>&lt;0.001). See FigureÂ 4. The reduction in prostate volume seen during the first 2Â years of double-blind treatment was maintained throughout an additional 2Â years of open-label extension studies.</p>
<p><span class="Bold">Figure 4. Prostate Volume Percent Change From Baseline (Randomized, Double-Blind, Placebo-Controlled Studies Pooled)</span></p>
<div class="Figure"><img alt="Figure 4. Prostate Volume Percent Change from Baseline (Randomized, Double-Blind, Placebo-Controlled Studies Pooled)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=813507ec-1fc1-420f-ac5c-5c794b1059cd&amp;name=12b15be8-c3de-4732-b9a7-1c06c5e6c385-05.jpg"></div>
<p><span class="Underline">Effect on Maximum Urine Flow Rate:</span> A mean peak urine flow rate (Q<span class="Sub">max</span>) of â‰¤15Â mL/sec was required for study entry. Q<span class="Sub">max </span>was approximately 10Â mL/sec at baseline across the 3Â pivotal studies.</p>
<p>Differences between the 2Â groups were statistically significant from baseline at MonthÂ 3 in all 3Â studies and were maintained through MonthÂ 12. At MonthÂ 12, the mean increase in Q<span class="Sub">max</span> across the 3Â studies pooled was 1.6Â mL/sec for AVODART and 0.7Â mL/sec for placebo; the mean difference (dutasteride minus placebo) was 0.8Â mL/sec (range: 0.7 to 1.0Â mL/sec in each of the 3Â studies, <span class="Italics">P</span>&lt;0.001). At MonthÂ 24, the mean increase in Q<span class="Sub">max</span> was 1.8Â mL/sec for dutasteride and 0.7Â mL/sec for placebo, with a mean difference of 1.1Â mL/sec (range: 1.0 to 1.2Â mL/sec in each of the 3Â studies, <span class="Italics">P</span>&lt;0.001). See FigureÂ 5. The increase in maximum urine flow rate seen during the first 2Â years of double-blind treatment was maintained throughout an additional 2Â years of open-label extension studies.</p>
<p><span class="Bold">Figure 5. Q<span class="Sub">max</span> Change From Baseline (Randomized, Double-Blind, Placebo-Controlled Studies Pooled)</span></p>
<div class="Figure"><img alt="Figure 5. Qmax Change from Baseline (Randomized, Double-Blind, Placebo-Controlled Studies Pooled)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=813507ec-1fc1-420f-ac5c-5c794b1059cd&amp;name=12b15be8-c3de-4732-b9a7-1c06c5e6c385-06.jpg"></div>
<p><span class="Underline">Summary of Clinical Studies:</span> Data from 3Â large, well-controlled efficacy studies demonstrate that treatment with AVODART (0.5Â mg once daily) reduces the risk of both AUR and BPH-related <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span> relative to placebo, improves BPH-related symptoms, decreases prostate volume, and increases maximum urinary flow rates. These data suggest that AVODART arrests the disease process of BPH in men with an <span class="product-label-link" type="condition" conceptid="4093346" conceptname="Large prostate">enlarged prostate</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d366473e-f29e-48c8-9c95-1a46bf616e32"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Combination With Alpha-Blocker Therapy (CombAT)</h2>
<p class="First"> The efficacy of combination therapy (AVODART 0.5Â mg/day plus tamsulosin 0.4Â mg/day, nÂ =Â 1,610) was compared with AVODART alone (nÂ =Â 1,623) or tamsulosin alone (nÂ =Â 1,611) in a 4-year multicenter, randomized, double-blind study. Study entry criteria were similar to the double-blind, placebo-controlled monotherapy efficacy trials described above in section 14.1. Eighty-eight percent (88%) of the enrolled study population was Caucasian. Approximately 52% of subjects had previous exposure to 5 alpha-reductase inhibitor or alpha adrenergic antagonist treatment. Of the 4,844Â subjects randomly assigned to receive treatment, 69% of subjects in the combination group, 67% in the group receiving AVODART, and 61% in the tamsulosin group completed 4Â years of double-blind treatment.</p>
<p><span class="Underline">Effect on Symptom Score:</span> Symptoms were quantified using the first 7Â questions of the International Prostate Symptom Score (IPSS) (identical to the AUA-SI). The baseline score was approximately 16.4Â units for each treatment group. Combination therapy was statistically superior to each of the monotherapy treatments in decreasing symptom score at MonthÂ 24, the primary time point for this endpoint. At MonthÂ 24 the mean changes from baseline (Â±SD) in IPSS total symptom scores were -6.2 (Â±7.14) for combination, -4.9 (Â±6.81) for AVODART, and -4.3 (Â±7.01) for tamsulosin, with a mean difference between combination and AVODART of -1.3Â units (<span class="Italics">P</span>&lt;0.001; [95% CI: -1.69, -0.86]), and between combination and tamsulosin of -1.8Â units (<span class="Italics">P</span>&lt;0.001; [95% CI: -2.23, -1.40]). A significant difference was seen by MonthÂ 9 and continued through MonthÂ 48. At Month 48 the mean changes from baseline (Â±SD) in IPSS total symptom scores were -6.3 (Â±7.40) for combination, -5.3 (Â±7.14) for AVODART, and -3.8 (Â±7.74) for tamsulosin, with a mean difference between combination and AVODART of -0.96Â units (<span class="Italics">P</span>&lt;0.001; [95% CI: -1.40, -0.52]), and between combination and tamsulosin of -2.5Â units (<span class="Italics">P</span>&lt;0.001; [95% CI: -2.96, -2.07]). See FigureÂ 6.</p>
<p><span class="Bold">Figure 6. International Prostate Symptom Score Change From Baseline Over a 48-Month Period (Randomized, Double-Blind, Parallel Group Study [CombAT Study])</span></p>
<div class="Figure"><img alt="Figure 6." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=813507ec-1fc1-420f-ac5c-5c794b1059cd&amp;name=12b15be8-c3de-4732-b9a7-1c06c5e6c385-07.jpg"></div>
<p>Â <span class="Underline">Effect on Acute <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary Retention</span> or the Need for BPH-Related Surgery:</span> After 4Â years of treatment, combination therapy with AVODART and tamsulosin did not provide benefit over monotherapy with AVODART in reducing the incidence of AUR or BPH-related surgery.</p>
<p><span class="Underline">Effect on Maximum Urine Flow Rate:</span>The baseline Q<span class="Sub">max</span> was approximately 10.7Â mL/sec for each treatment group. Combination therapy was statistically superior to each of the monotherapy treatments in increasing Q<span class="Sub">max</span> at MonthÂ 24, the primary time point for this endpoint. At MonthÂ 24, the mean increases from baseline (Â±SD) in Q<span class="Sub">max</span> were 2.4Â (Â±5.26)Â mL/sec for combination, 1.9Â (Â±5.10)Â mL/sec for AVODART, and 0.9Â (Â±4.57)Â mL/sec for tamsulosin, with a mean difference between combination and AVODART of 0.5Â mL/sec (<span class="Italics">P</span>Â =Â 0.003; [95% CI: 0.17, 0.84]), and between combination and tamsulosin of 1.5Â mL/sec (<span class="Italics">P</span>&lt;0.001; [95% CI: 1.19, 1.86]). This difference was seen by MonthÂ 6 and continued through MonthÂ 24. See Figure 7.</p>
<p> The additional improvement in Q<span class="Sub">max</span> of combination therapy over monotherapy with AVODART was no longer statistically significant at Month 48. </p>
<p><span class="Bold">Figure 7. Q<span class="Sub">max</span> Change From Baseline Over a 24-Month Period (Randomized, Double-Blind, Parallel Group Study [CombAT Study])</span></p>
<div class="Figure"><img alt="Figure 7. Q-max Change Ffrom Baseline Over a 24-Month Period (Randomized, Double-Blind, Parallel Group Study [CombAT Study])" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=813507ec-1fc1-420f-ac5c-5c794b1059cd&amp;name=12b15be8-c3de-4732-b9a7-1c06c5e6c385-08.jpg"></div>
<p><span class="Underline">Effect on Prostate Volume:</span> The mean prostate volume at study entry was approximately 55Â cc. At MonthÂ 24, the primary time point for this endpoint, the mean percent changes from baseline (Â±SD) in prostate volume were -26.9% (Â±22.57) for combination therapy, <br>-28.0% (Â±24.88) for AVODART, and 0% (Â±31.14) for tamsulosin, with a mean difference between combination and AVODART of 1.1% (<span class="Italics">P</span>Â =Â NS; [95% CI: -0.6, 2.8]), and between combination and tamsulosin of -26.9% (<span class="Italics">P</span>&lt;0.001; [95% CI: -28.9, -24.9]). Similar changes were seen at MonthÂ 48: -27.3% (Â±24.91) for combination therapy, -28.0% (Â±25.74) for AVODART, and +4.6% (Â±35.45) for tamsulosin.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_a321524b-278e-417e-985d-ffe574993d74"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">AVODART Soft Gelatin Capsules 0.5Â mg are oblong,
opaque, dull yellow, gelatin capsules imprinted with â€œGXÂ CE2â€? with red
edible ink on one side packaged in <br></p>
<a name="i665611cb-91a4-4adb-85d6-ad520ca96e4f"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>bottles of 30<br>
</td>
<td>NDC 54868-5114-0<br>
</td>
</tr>
<tr class="Last">
<td>bottles of 90<br>
</td>
<td>NDC 54868-5114-1<br>
</td>
</tr>
</tbody></table>
<p>with child-resistant closures.</p>
<p>Store at 25Â°C (77Â°F); excursions permitted to 15-30Â°C (59-86Â°F) [see USP Controlled Room Temperature].</p>
<p>Dutasteride is absorbed through the skin. AVODART Capsules should not be handled by women who are pregnant or who could become pregnant because of the potential for absorption of dutasteride and the subsequent potential risk to a developing male fetus <span class="Italics">[see Warnings and Precautions (5.4)]</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_c4040461-3213-4d59-9e48-1b2741244da7"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-approved patient labeling (Patient Information).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0ed21475-e00e-4b3e-b5a5-e5acad934d82"></a><a name="section-15.1"></a><p></p>
<h2>17.1 PSA Monitoring</h2>
<p class="First"> Physicians should inform patients that AVODART reduces serum PSA levels by approximately 50% within 3 to 6 months of therapy, although it may vary for each individual. For patients undergoing PSA screening, increases in PSA levels while on treatment with AVODART may signal the presence of prostate cancer and should be evaluated by a healthcare provider <span class="Italics">[see Warnings and Precautions (5.1)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_10ddfdec-5790-4c95-93c1-5eeb9bcc4592"></a><a name="section-15.2"></a><p></p>
<h2>17.2 Increased Risk of High-grade Prostate Cancer</h2>
<p class="First"> Physicians should inform patients that there was an increase in high-grade prostate cancer in men treated with 5 alpha-reductase inhibitors (which are indicated for BPH treatment), including AVODART, compared with those treated with placebo in studies looking at the use of these drugs to reduce the risk of prostate cancer <span class="Italics">[see Indications and Usage (1.3), Warnings and Precautions (5.2), Adverse Reactions (6.1)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c3fb6bc4-c2fa-42cc-8d28-12d21fd12280"></a><a name="section-15.3"></a><p></p>
<h2>17.3 Exposure of Womenâ€”Risk to Male Fetus</h2>
<p class="First"> Physicians should inform patients that AVODART Capsules should not be handled by a woman who is pregnant or who could become pregnant because of the potential for absorption of dutasteride and the subsequent potential risk to a developing male fetus. Dutasteride is absorbed through the skin and could result in unintended fetal exposure. If a pregnant woman or woman of childbearing potential comes in contact with leaking AVODART Capsules, the contact area should be washed immediately with soap and water <span class="Italics">[see Warnings and Precautions (5.4), Use in Specific Populations (8.1)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cce6fd99-262d-4f50-aa53-d3e1b14f1017"></a><a name="section-15.4"></a><p></p>
<h2>17.4 Blood Donation</h2>
<p class="First"> Physicians should inform men treated with AVODART that they should not donate blood until at least 6Â months following their last dose to prevent pregnant women from receiving dutasteride through blood transfusion <span class="Italics">[see Warnings and Precautions (5.5)]</span>. Serum levels of dutasteride are detectable for 4 to 6Â months after treatment ends <span class="Italics">[see Clinical Pharmacology (12.3)]</span>.</p>
<p>GlaxoSmithKline<br>Research Triangle Park, NC 27709</p>
<p>Manufactured by Catalent Pharma Solutions</p>
<p>Somerset, NJ 08873 for<br>GlaxoSmithKline, Research Triangle Park, NC 27709</p>
<p>Â©2011, GlaxoSmithKline. All rights reserved.</p>
<p>October 2011<br>AVT:8PI</p>
<br><p>Additional barcode label applied by:<br>Physicians Total Care, Inc.<br>Tulsa, OklahomaÂ Â Â Â  74146<br></p>
<p><br></p>
<p>Â </p>
<p><span class="Bold">PHARMACIST-DETACH HERE AND GIVE INSTRUCTIONS TO PATIENT</span></p>
<p>------------------------------------------------------------------------------------------------</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="i4i_patient_package_insert_id_103205cf-dd20-4580-a611-1b4afcdb213b"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">PATIENT INFORMATION</span></p>
<p>Â <span class="Bold">AVODART<span class="Sup">Â®</span> (avâ€™ Å? dart)</span></p>
<p><span class="Bold">(dutasteride) Capsules</span></p>
<p><span class="Bold">AVODART is for use by men only.</span></p>
<p>Read this patient information before you start taking AVODART and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or your treatment.</p>
<p><span class="Bold">What is AVODART?</span></p>
<p>AVODART is a prescription medicine that contains dutasteride. AVODART is used to treat the symptoms of <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">benign prostatic hyperplasia</span> (BPH) in men with an <span class="product-label-link" type="condition" conceptid="4093346" conceptname="Large prostate">enlarged prostate</span> to:</p>
<ul>
<li>Improve symptoms</li>
<li>Reduce the risk of acute <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> (a complete blockage of urine flow)</li>
<li>Reduce the risk of the need for BPH-related surgery</li>
</ul>
<p><span class="Bold">Who should NOT take AVODART?</span></p>
<p><span class="Bold">Do Not Take AVODART if you are:</span></p>
<ul>
<li>pregnant or could become pregnant. AVODART may harm your unborn baby. Pregnant women should not touch AVODART Capsules. If a woman who is pregnant with a male baby gets enough AVODART in her body by swallowing or touching AVODART, the male baby may be born with sex organs that are not normal. If a pregnant woman or woman of childbearing potential comes in contact with leaking AVODART Capsules, the contact area should be washed immediately with soap and water.</li>
<li>a child or a teenager.</li>
<li>allergic to dutasteride or any of the ingredients in AVODART. See the end of this leaflet for a complete list of ingredients in AVODART.</li>
<li>allergic to other 5 alpha-reductase inhibitors, for example, PROSCAR (finasteride) Tablets.</li>
</ul>
<p><span class="Bold">What should I tell my healthcare provider before taking AVODART?</span></p>
<p><span class="Bold">Before you take AVODART, tell your healthcare provider if you:</span></p>
<ul><li>have liver problems</li></ul>
<p>Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. AVODART and other medicines may affect each other, causing side effects. AVODART may affect the way other medicines work, and other medicines may affect how AVODART works.</p>
<p>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take AVODART?</span></p>
<ul>
<li>Take 1 AVODART capsule once a day.</li>
<li>Swallow AVODART capsules whole. Do not crush, chew, or open AVODART capsules because the contents of the capsule may irritate your lips, mouth, or throat.</li>
<li>You can take AVODART with or without food.</li>
<li>If you miss a dose, you may take it later that day. Do not make up the missed dose by taking 2Â doses the next day.</li>
</ul>
<p><span class="Bold">What should I avoid while taking AVODART?</span></p>
<ul><li>You should not donate blood while taking AVODART or for 6 months after you have stopped AVODART. This is important to prevent pregnant women from receiving AVODART through blood transfusions.</li></ul>
<p><span class="Bold">What are the possible side effects of AVODART?</span></p>
<p><span class="Bold">AVODART may cause serious side effects, including:</span></p>
<ul><li>
<span class="Bold">Rare and serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, including:</span><ul>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, tongue, or throat</li>
<li>serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, such as <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">skin peeling</span></li>
</ul>
</li></ul>
<p>Get medical help right away if you have these serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>. </p>
<ul><li><span class="Bold">Higher chance of a more serious form of prostate cancer.</span></li></ul>
<p>The most common side effects of AVODART include:</p>
<ul>
<li>trouble getting or keeping an erection (<span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>)</li>
<li>a decrease in sex drive (libido)</li>
<li>ejaculation problems</li>
<li>enlarged or painful breasts. If you notice <span class="product-label-link" type="condition" conceptid="80767" conceptname="Breast lump">breast lumps</span> or <span class="product-label-link" type="condition" conceptid="4181744" conceptname="Discharge from nipple">nipple discharge</span>, you should talk to your healthcare provider.</li>
</ul>
<p>AVODART has been shown to reduce sperm count, semen volume, and sperm movement. However, the effect of AVODART on male fertility is not known.</p>
<p><span class="Bold">Prostate Specific Antigen (PSA) Test:</span> Your healthcare provider may check you for other prostate problems, including prostate cancer before you start and while you take AVODART. A blood test called PSA (prostate-specific antigen) is sometimes used to see if you might have prostate cancer. AVODART will reduce the amount of PSA measured in your blood. Your healthcare provider is aware of this effect and can still use PSA to see if you might have prostate cancer. Increases in your PSA levels while on treatment with AVODART (even if the PSA levels are in the normal range) should be evaluated by your healthcare provider.</p>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects with AVODART. For more information, ask you healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store AVODART?</span></p>
<ul>
<li>Store AVODART Capsules at room temperature (59Â°F to 86Â°F or 15Â°C to 30Â°C).</li>
<li>AVODART Capsules may become deformed and/or discolored if kept at <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">high temperatures</span>.</li>
<li>Do not use AVODART if your capsules are deformed, discolored, or leaking.</li>
<li>Safely throw away medicine that is no longer needed.</li>
</ul>
<p>Keep AVODART and all medicines out of the reach of children.</p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a patient leaflet. Do not use AVODART for a condition for which it was not prescribed. Do not give AVODART to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>This patient information leaflet summarizes the most important information about AVODART. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about AVODART that is written for health professionals.</p>
<p>For more information, go to <a href="http://www.tradename.com/">www.AVODART.com</a> or call1-888-825-5249.</p>
<p><span class="Bold">What are the ingredients in AVODART?</span></p>
<p><span class="Bold">Active ingredient: </span>dutasteride. </p>
<p><span class="Bold">Inactive ingredients:</span> butylated hydroxytoluene, ferric oxide (yellow), gelatin (from certified BSE-free bovine sources), glycerin, mono-di-glycerides of caprylic/capric acid, titanium dioxide, and edible red ink.</p>
<p><span class="Bold">How does AVODART work?</span></p>
<p>Prostate growth is caused by a hormone in the blood called dihydrotestosterone (DHT). AVODART lowers DHT production in the body, leading to shrinkage of the <span class="product-label-link" type="condition" conceptid="4093346" conceptname="Large prostate">enlarged prostate</span> in most men. While some men have fewer problems and symptoms after 3Â months of treatment with AVODART, a treatment of period of at least 6 months is usually necessary to see if AVODART will work for you.</p>
<p>GlaxoSmithKline<br>Research Triangle Park, NC 27709</p>
<p>Manufactured by Catalent Pharma Solutions<br>Somerset, NJ 08873 for<br>GlaxoSmithKline<br>Research Triangle Park, NC 27709</p>
<p>Â©2011, GlaxoSmithKline. All rights reserved.</p>
<p>October 2011<br>AVT:5PIL</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_a60bf5a2-2352-4ad8-9085-a80fa52674b1"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL</span></p>
<p><img alt="Avodart 0.5 mg capsules label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=813507ec-1fc1-420f-ac5c-5c794b1059cd&amp;name=5114.jpg"></p>
<p><span class="Bold">AVODART<span class="Sup">Â®</span></span></p>
<p><span class="Bold">(dutasteride)</span></p>
<p><span class="Bold">Soft Gelatin Capsules</span></p>
<p><span class="Bold">0.5 mg</span></p>
<p><span class="Bold">R<span class="Sub">X</span> only</span></p>
<p>GX CE2</p>
<p><span class="Bold"><br></span></p>
<p><span class="Bold">WARNING: AVODART should not be used by women</span><span class="Bold">or children. Women who are or may potentially</span><span class="Bold">be pregnant should not use or handle AVODART </span><span class="Bold">Soft Gelatin Capsules (see prescribing information).</span><span class="Bold">If contact is made with leaking capsule, wash</span><span class="Bold">immediately with soap and water. </span></p>
<p>Each capsule contains 0.5 mg dutasteride.</p>
<p><span class="Bold">Usual Dosage:</span> 0.5 mg once a day.</p>
<p>Capsules should be swallowed whole and not chewed or opened. See prescribing information for further dosing information.</p>
<p>Store at 25<span class="Sup">o</span>C (77<span class="Sup">o</span>F); excursions permitted to 15-30<span class="Sup">o</span>C (59-86<span class="Sup">o</span>F) [see USP Controlled Room Temperature].</p>
<p>Do not use if printed safety seal under cap is broken or missing.</p>
<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>AVODARTÂ 		
					</strong><br><span class="contentTableReg">dutasteride capsule, liquid filled</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5114(NDC:0173-0712)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DUTASTERIDE</strong> (DUTASTERIDE) </td>
<td class="formItem">DUTASTERIDE</td>
<td class="formItem">0.5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BUTYLATED HYDROXYTOLUENE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CAPRYLIC/CAPRIC MONO/DIGLYCERIDES</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (dull yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (soft gelatin capsule) </td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">GX;CE2</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5114-0</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-5114-1</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021319</td>
<td class="formItem">07/16/2004</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>c00a9dd4-45c6-4de5-bfb7-9abdaac6bbcd</div>
<div>Set id: 813507ec-1fc1-420f-ac5c-5c794b1059cd</div>
<div>Version: 2</div>
<div>Effective Time: 20111220</div>
</div>
</div>Â <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
